Fractyl Health, Inc. (GUTS) Income Statement
GUTS FY2025 at a glance
Fiscal year ended September 30, 2025 · U.S. dollarsGUTS revenue and net income
GUTS profit margins
GUTS growth rates
to FY2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −100.0% | — | — | — |
| Gross profit | −2,725.6% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
GUTS quarterly EPS vs estimates
Fractyl Health beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 11, 2026 (estimate $-1.62).
GUTS income statement
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $93,000 | $120,000 | $0 | $0 | $0 | $0 |
| Cost of revenue | $1.1M | $50,000 | $77,000 | $452,000 | $676,000 | $770,000 | $893,000 |
| Gross profit | −$1.1M | $43,000 | $43,000 | −$452,000 | −$676,000 | −$770,000 | −$893,000 |
| Research & development | $74.5M | $70.5M | $38.0M | $34.4M | $26.4M | $22.4M | $20.9M |
| Sales, general & admin | $22.3M | $23.1M | $12.8M | $15.5M | $11.2M | $6.5M | $9.0M |
| Total operating expenses | $96.8M | $93.6M | $50.9M | $48.9M | $36.9M | $28.2M | $29.0M |
| Operating income | −$96.8M | −$93.5M | −$50.8M | −$49.4M | −$36.9M | −$29.0M | −$29.9M |
| Interest income | $1.5M | $4.1M | $1.3M | $797,000 | — | — | — |
| Interest expense | — | — | — | — | $1.4M | $1.5M | $635,000 |
| Income before taxes | −$141.0M | −$68.7M | −$77.1M | −$46.5M | −$38.7M | −$30.5M | −$30.6M |
| Net income | −$141.0M | −$68.7M | −$77.1M | −$46.5M | −$38.7M | −$30.5M | −$30.6M |
| EBITDA | −$139.8M | −$68.0M | −$50.5M | −$46.0M | −$36.6M | −$28.2M | −$29.0M |
| EPS (diluted) | −$2.29 | −$0.96 | −$1.62 | −$0.98 | −$0.81 | −$0.64 | — |
| Gross margin | — | 46.2% | 35.8% | — | — | — | — |
| Operating margin | — | −100,571.0% | −42,363.3% | — | — | — | — |
| Net margin | — | −73,864.5% | −64,242.5% | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $3,000 | $14,000 | $43,000 | $33,000 | $7,000 | $36,000 |
| Cost of revenue | $0 | — | $279,000 | $290,000 | $270,000 | $290,000 | −$53,000 | $7,000 | $24,000 | $19,000 | $40,000 | $109,000 |
| Gross profit | $0 | — | −$279,000 | −$290,000 | −$270,000 | −$290,000 | $3,000 | $7,000 | $19,000 | $14,000 | −$33,000 | −$73,000 |
| Research & development | $13.8M | $15.6M | $16.5M | $17.5M | $21.2M | $19.4M | $20.3M | $19.0M | $16.8M | $14.4M | $10.2M | $9.4M |
| Sales, general & admin | $5.3M | $5.2M | $6.8M | $5.2M | $4.9M | $5.3M | $4.9M | $4.8M | $6.2M | $7.1M | $2.8M | $5.5M |
| Total operating expenses | $19.1M | $20.8M | $23.3M | $22.7M | $26.1M | $24.8M | $25.2M | $23.8M | $23.0M | $21.6M | $12.9M | $13.8M |
| Operating income | −$19.1M | −$20.8M | −$23.3M | −$22.7M | −$26.1M | −$24.8M | −$25.2M | −$23.8M | −$23.0M | −$21.5M | −$13.0M | −$13.9M |
| Interest income | $431,000 | $593,000 | $645,000 | $166,000 | $226,000 | $503,000 | $726,000 | $947,000 | $1.4M | $1.1M | $463,000 | $226,000 |
| Income before taxes | −$25.5M | $9.2M | −$43.7M | −$45.6M | −$27.9M | −$23.7M | −$25.0M | −$23.2M | −$17.2M | −$3.3M | −$19.2M | −$15.7M |
| Net income | −$25.5M | $9.2M | −$43.7M | −$45.6M | −$27.9M | −$23.7M | −$25.0M | −$23.2M | −$17.2M | −$3.3M | −$19.2M | −$15.7M |
| EBITDA | −$25.3M | $9.5M | −$43.4M | −$45.3M | −$27.6M | −$23.4M | −$24.7M | −$23.0M | −$17.0M | −$3.3M | −$12.9M | −$15.7M |
| EPS (diluted) | −$0.12 | $0.06 | −$0.07 | −$0.71 | −$0.57 | −$0.49 | −$0.52 | −$0.43 | −$0.36 | −$0.17 | — | — |
| Gross margin | — | — | — | — | — | — | 100.0% | 50.0% | 44.2% | 42.4% | −471.4% | −202.8% |
| Operating margin | — | — | — | — | — | — | −840,333.3% | −169,957.1% | −53,453.5% | −65,278.8% | −185,442.9% | −38,536.1% |
| Net margin | — | — | — | — | — | — | −832,333.3% | −165,521.4% | −40,067.4% | −10,066.7% | −274,000.0% | −43,741.7% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in GUTS's financial statements (latest annual report filed March 24, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
GUTS financial results
Fractyl Health reported no revenue in fiscal year 2025 (ended September 30, 2025). It had a net loss of $141.0 million. Diluted earnings per share came to −$2.29.
See the GUTS stock overview for the latest quote and news, or the GUTS chart for price history and technical indicators.
GUTS income statement FAQ
Does Fractyl Health have revenue?
Fractyl Health reported no revenue for fiscal year 2025, which ended on September 30, 2025.
Is Fractyl Health profitable?
No. Fractyl Health reported a net loss of $141.0 million in fiscal 2025.
How much does Fractyl Health spend on research and development?
Fractyl Health spent $74.5 million on research and development in fiscal 2025.
What are Fractyl Health's earnings per share?
Fractyl Health earned $-2.29 per diluted share in fiscal 2025, compared with $-0.96 a year earlier.
When will Fractyl Health report its next earnings?
Fractyl Health is expected to report results for the quarter ending September 30, 2026 on November 11, 2026 after the market closes.
When does Fractyl Health's fiscal year end?
Fractyl Health's fiscal year ends in September. The latest annual report covers the year ended September 30, 2025 and was filed on March 24, 2026.